Citius Pharmaceuticals, Inc. (CTXR) - 10-Q Summary
Business Context and Reporting Period
Period: Three months ended December 31, 2025 (Q1 Fiscal 2026).
Business Overview: Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on oncology, anti-infectives, and stem cell therapies. The company operates through its majority-owned subsidiary, Citius Oncology (CTOR), which commercializes LYMPHIR (denileukin diftitox) for cutaneous T-cell lymphoma (CTCL). The company also develops Mino-Lok (anti-infective) and NoveCite (stem cell therapy).
Key Event: Commercial sales of LYMPHIR commenced in December 2025, marking the company's first revenue-generating period.
Key Financial Metrics
| Metric | Q1 2026 (Dec 31, 2025) | Q1 2025 (Dec 31, 2024) |
|---|---|---|
| Revenue | $3,944,111 | $0 |
| Gross Profit | $3,154,903 | $0 |
| Gross Margin | 80.0% | N/A |
| Net Loss | $(9,393,889) | $(10,281,246) |
| Net Loss Per Share (Basic/Diluted) | $(0.38) | $(1.30) |
| Cash and Equivalents | $7,721,393 | $1,100,079 |
| Working Capital | $(262,000) | Negative |
| Total Debt (Current) | $1,000,000 (Note Payable) | $1,000,000 |
| License Payable | $18,250,000 | $22,650,000 |
Cash Flow: Net cash used in operating activities was $13.0 million. Net cash provided by financing activities was $20.9 million, driven by equity offerings from both Citius Pharma and Citius Oncology.
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from zero revenue to $3.9 million in net revenue, driven by the December 2025 launch of LYMPHIR.
- Amortization: Amortization of in-process research and development (IPR&D) began in Q1 2026 ($573,438) following revenue recognition, compared to $0 in the prior year.
- Stock-Based Compensation: Increased to $4.28 million from $2.52 million, primarily due to restricted stock awards granted to Citius Oncology employees in September 2025.
- Liquidity: Cash balances increased significantly from $1.1 million to $7.7 million due to successful capital raises in October and December 2025.
- Debt Obligations: A $1 million note payable was extended in December 2025 and paid in full in January 2026 (subsequent event).
Outlook, Risks, and Contingencies
- Going Concern: The filing includes a "substantial doubt" warning regarding the company's ability to continue as a going concern. Management estimates cash resources will fund operations only through May 2026. Additional capital is required immediately thereafter.
- Capital Raising: The company is actively engaged in capital raising initiatives. Citius Oncology has retained Jefferies LLC to evaluate strategic alternatives.
- Nasdaq Compliance: On February 9, 2026, the company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the stock price closing below $1.00 for 30 consecutive days. The company has 180 days (until August 10, 2026) to regain compliance.
- Major Obligations:
- Dr. Reddy's: $18.25 million milestone payment remains due (partially deferred).
- Eisai: Approximately $6.8 million in unpaid invoices remains outstanding.
- Manufacturing: Minimum purchase commitments of approximately $16.2 million for drug substance and $4.0 million for finished goods packaging.
- Regulatory: Future success depends on regulatory approval for Mino-Lok and continued commercialization of LYMPHIR.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the May 2026 liquidity horizon.
- Debt Settlement: Confirm the status of the $18.25 million milestone payment to Dr. Reddy's and the $6.8 million owed to Eisai.
- Nasdaq Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement by August 2026.
- Revenue Sustainability: Assess whether Q1 2026 revenue from LYMPHIR is sustainable or if it was driven by initial channel loading.
- Dilution Risk: Review the impact of outstanding warrants (approx. 46.8 million for Citius Oncology and 18.7 million for Citius Pharma) on future share count.